Canadian universities are making a bold move to keep the economic benefits of their research within the country. The University of Toronto (U of T) and McMaster University have joined forces to launch a $40-million venture capital fund, the Genesys University Seed Fund, to support life sciences startups, primarily spinouts from these institutions. This initiative is a significant step towards addressing the long-standing issue of Canadian researchers' discoveries being commercialized abroad, often resulting in financial gains for other countries. The fund is a response to the lack of domestic institutional investors in Canadian life sciences venture capital and the underperformance of these funds compared to software and clean technology peers. It also builds on the success of similar efforts by other universities, such as the University of Calgary and the University of Waterloo, which have launched seed funds to finance their spinouts. The Genesys fund is managed by Genesys Capital, a Toronto-based venture capital firm, and is supported by various investors, including the Ontario government, the Temerty Foundation, and Royal Bank of Canada. The fund will focus on medical devices and drugs targeting cancer and heart and brain ailments, aiming to advance discoveries to have real-world impact. The initiative is a testament to the universities' commitment to fostering innovation and entrepreneurship, and it represents a significant step towards building a robust life sciences sector in Canada. However, the question remains: will this fund be enough to change the trajectory of Canadian research and innovation, or is it just a drop in the ocean? Only time will tell. But one thing is certain: the universities are taking a proactive approach to keep the economic benefits of their research within the country, and that is a positive step forward.
